Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1945]

Highlights of the 22nd EACR meeting and tackling glioblastoma

Dr Joan Seoane – Vall d’Hebron Institute of Oncology, Spain

Highlights of the 22nd EACR meeting and tackling glioblastoma ( Dr Joan Seoane – Vall d’Hebron Institute of Oncology, Spain )

Strategies to improve the tolerability of treatment in patients with multiple...

Prof Michel Delforge - Catholic University, Leuven, Belgium

Strategies to improve the tolerability of treatment in patients with multiple myeloma ( Prof Michel Delforge - Catholic University, Leuven, Belgium )

EHA 2012 advances in lymphoma; lenalidamide and beyond

Prof John Gribben - Barts & The London Trust Cancer Centre, UK; Prof Gilles...

EHA 2012 advances in lymphoma; lenalidamide and beyond ( Prof John Gribben - Barts & The London Trust Cancer Centre, UK; Prof Gilles Salles - Universite Claude Bernard, Lyon, France )

New drugs for relapsed and refractory Hodgkin's lymphoma

Prof Anas Younes - MD Anderson Cancer Center, Houston, USA

$New drugs for relapsed and refractory Hodgkin's lymphoma ( Prof Anas Younes - MD Anderson Cancer Center, Houston, USA )$

How malignant cells in patients with CLL escape T-cell recognition

Dr Alan G Ramsay - Barts Cancer Institute, Queen Mary University of London, UK

How malignant cells in patients with CLL escape T-cell recognition ( Dr Alan G Ramsay - Barts Cancer Institute, Queen Mary University of London, UK )

Impressive results with a bispecific antibody for ALL

Prof Max Topp - University of Wuerzberg, Germany

Impressive results with a bispecific antibody for ALL ( Prof Max Topp - University of Wuerzberg, Germany )

Insight in to the EMILIA trial and systemic challenges with neoadjuvant therapy

Dr Erica Mayer - Dana-Farber Cancer Institute, Boston, MA, USA

Insight in to the EMILIA trial and systemic challenges with neoadjuvant therapy ( Dr Erica Mayer - Dana-Farber Cancer Institute, Boston, MA, USA )

ASCO 2012 Drug Development Research Professorship

Dr Alex Adjei - Roswell Park Cancer Institute, Las Vegas, USA

ASCO 2012 Drug Development Research Professorship ( Dr Alex Adjei - Roswell Park Cancer Institute, Las Vegas, USA )

Acute Lymphocytic Leukemia: impressive results with a bispecific antibody in...

Prof Max Topp - University of Wuerzberg, Germany

$Acute Lymphocytic Leukemia: impressive results with a bispecific antibody in patients with refractory disease ( Prof Max Topp - University of Wuerzberg, Germany )$

How malignant cells in patients with CLL escape T-cell recognition

Dr Alan G Ramsay - Barts Cancer Institute, Queen Mary University of London, UK

How malignant cells in patients with CLL escape T-cell recognition ( Dr Alan G Ramsay - Barts Cancer Institute, Queen Mary University of London, UK )

Early results from new PD-1 targeted immune therapy

Dr Suzanne Topalian - Johns Hopkins University School of Medicine, Baltimore...

Early results from new PD-1 targeted immune therapy ( Dr Suzanne Topalian - Johns Hopkins University School of Medicine, Baltimore, USA )

Targeting DNA damage response and repair excluding PARP for triple negative...

Prof Thomas Helleday - Karolinska Institutet, Stockholm, Sweden

Targeting DNA damage response and repair excluding PARP for triple negative breast cancer ( Prof Thomas Helleday - Karolinska Institutet, Stockholm, Sweden )

More from ecancer